8 results on '"Montaleytang, Maeva"'
Search Results
2. Telemedication Reviews to Optimize Medication Prescription for Older People in Nursing Homes
- Author
-
Berard, Charlotte, primary, Di Mascio, Thomas, additional, Montaleytang, Maeva, additional, Couderc, Anne Laure, additional, Villani, Patrick, additional, Honoré, Stephane, additional, Daumas, Aurelie, additional, and Correard, Florian, additional
- Published
- 2022
- Full Text
- View/download PDF
3. Hydrophilic Fluorescent Nanoprodrug of Paclitaxel for Glioblastoma Chemotherapy
- Author
-
Daniel, Jonathan, Montaleytang, Maeva, Nagarajan, Sounderya, Picard, Sébastien, Clermont, Guillaume, Lazar, Adina, Dumas, Noé, Correard, Florian, Braguer, Diane, Blanchard-Desce, Mireille, Esteve, Marie-Anne, Vaultier, Michel, Institut des Sciences Moléculaires (ISM), Université Montesquieu - Bordeaux 4-Université Sciences et Technologies - Bordeaux 1-École Nationale Supérieure de Chimie et de Physique de Bordeaux (ENSCPB)-Centre National de la Recherche Scientifique (CNRS), Institut des Sciences Chimiques de Rennes (ISCR), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Ecole Nationale Supérieure de Chimie de Rennes-Centre National de la Recherche Scientifique (CNRS), emlyon business school, Laboratoire de Neuropathologie Raymond Escourolle, CHU Pitié-Salpêtrière [APHP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Sorbonne Université (SU), Université Grenoble Alpes - UFR Pharmacie (UGA UFRP), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre de Recherches en Oncologie biologique et Oncopharmacologie (CRO2), Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM), Synthèse et électrosynthèse organiques (SESO), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS), Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Ecole Nationale Supérieure de Chimie de Rennes (ENSCR)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), ANR-10-IDEX-03-02, Agence Nationale de la Recherche, 2018-08, Institut National Du Cancer, Canceropôle PACA, PC201420, L?Institut Th?matique Multi-Organisme Cancer d'Aviesan, Université Grenoble Alpes - UFR Pharmacie [ ?-2019] (UGA UFRP [ ?-2019]), Université Montesquieu - Bordeaux 4-Université Sciences et Technologies - Bordeaux 1 (UB)-École Nationale Supérieure de Chimie et de Physique de Bordeaux (ENSCPB)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Montesquieu - Bordeaux 4-Université Sciences et Technologies - Bordeaux 1-École Nationale Supérieure de Chimie et de Physique de Bordeaux (ENSCPB)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Aix Marseille Université (AMU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Blanchard-Desce, Mireille, and Laboratoire de Neuropathologie Raymond Escourolle [CHU Pitié-Salpétriêre]
- Subjects
Chemistry ,[CHIM.THER] Chemical Sciences/Medicinal Chemistry ,[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,[CHIM.THER]Chemical Sciences/Medicinal Chemistry ,QD1-999 ,Article ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience; Highly water-soluble, nontoxic organic nano-particles on which paclitaxel (PTX), a hydrophobic anticancer drug, has been covalently bound via an ester linkage (4.5% of total weight) have been prepared for the treatment of glioblastoma. These soft fluorescent organic nanoparticles (FONPs), obtained from citric acid and diethylenetriamine by microwave-assisted condensation, show suitable size (Ø = 17− 30 nm), remarkable solubility in water, softness as well as strong blue fluorescence in an aqueous environment that are fully retained in cell culture medium. Moreover, these FONPs were demonstrated to show in vitro safety and preferential internalization in glioblastoma cells through caveolin/lipid raft-mediated endocytosis. The PTX-conjugated FONPs retain excellent solubility in water and remain stable in water (no leaching), while they showed anticancer activity against glioblastoma cells in two-dimensional and three-dimensional culture. PTX-specific effects on microtubules reveal that PTX is intracellularly released from the nanocarriers in its active form, in relation with an intracellular-promoted lysis of the ester linkage. As such, these hydrophilic prodrug formulations hold major promise as biocompatible nanotools for drug delivery.
- Published
- 2019
4. Acceptability of a Novel Telemedication Review for Older Adults in Nursing Homes in France: A Qualitative Study
- Author
-
Costa, Marie, primary, Correard, Florian, additional, Montaleytang, Maeva, additional, Baumstarck, Karine, additional, Loubière, Sandrine, additional, Amichi, Kahena, additional, Villani, Patrick, additional, Honore, Stephane, additional, Daumas, Aurélie, additional, and Verger, Pierre, additional
- Published
- 2021
- Full Text
- View/download PDF
5. Évaluation clinique de l’expertise médico-pharmaceutique en gériatrie
- Author
-
Montaleytang, Maeva, Aix-Marseille Université - Faculté de pharmacie (AMU PHARM), Aix Marseille Université (AMU), and Florian Correard
- Subjects
Polymédication ,[SDV]Life Sciences [q-bio] ,Iatrogénie médicamenteuse ,Révision des thérapeutiques ,Télé-expertise ,EHPAD ,[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences ,Conciliation - Abstract
D’après l'Organisation Mondiale de la Santé (OMS), entre 2000 et 2050, la proportion de la population mondiale de plus de 60 ans doublera pour passer d’environ 11 % à 22 %. Avec l’âge grandissant, la fréquence de la poly-pathologie augmente ainsi que la poly-médication qui y est associée. Cette poly-médication peut être à l’origine d’interactions médicamenteuses, d’effets indésirables mais également d’une observance diminuée. La révision systématique des prescriptions est apparue depuis longtemps comme une solution simple et efficace pour limiter la iatrogénie médicamenteuse chez la personne âgée et les effets indésirables directement associés. Cette révision thérapeutique, qui peut intervenir à différentes étapes du parcours de soins, nécessite d’être développée et évaluée afin de déterminer l’ensemble des facteurs favorisant ou limitant son impact. À l’AP-HM, différentes actions ont été mises en place permettant la réalisation d’un bilan de médication (BM) médico-pharmaceutique pour les patients hospitalisés ou pour les patients résidents d’Ehpad dans le cadre de télé-expertise à distance. Les différentes études présentées évaluent l’impact du BM sur le maintien, par le médecin généraliste, des prescriptions de sortie d’hospitalisation ; l’impact du BM sur le taux de ré-hospitalisations non programmées et/ou de décès à 30 jours après la sortie d’hospitalisation et l’impact de la télé-expertise médicamenteuse (BM à distance) sur le taux d’hospitalisations non programmées de patients résidents d’Ehpad.
- Published
- 2020
6. Télémédecine et iatrogénie médicamenteuse en Ehpad
- Author
-
Montaleytang, Maeva, primary, Correard, Florian, additional, Delalande, Géraldine, additional, Bourriquen, Maryline, additional, and Daumas, Aurélie, additional
- Published
- 2019
- Full Text
- View/download PDF
7. Telemedication Reviews to Optimize Medication Prescription for Older People in Nursing Homes.
- Author
-
Berard C, Di Mascio T, Montaleytang M, Couderc AL, Villani P, Honoré S, Daumas A, and Correard F
- Subjects
- Aged, Drug Prescriptions, Humans, Inappropriate Prescribing prevention & control, Nursing Homes, Polypharmacy, General Practitioners, Telemedicine
- Abstract
Introduction: Older people living in nursing homes (NH) are at a higher risk of preventable drug-related adverse events because of age-related physiological changes, polypathology, and polypharmacy. NH residents are particularly exposed to potentially inappropriate medications (PIMs). Many strategies have been developed to improve the quality and the safety of drug prescription in NH, including medication reviews (MRs). Methods: In the context of the application of telemedicine, we developed and are currently implementing a novel hospital expert-based MRs through tele-expertise (or "telemedication review," telemedication reviews hereafter [TMR]) in French NH residents. The impact of these TMR on unplanned hospitalizations 3 months after implementation is assessed. TMR consider all available sociodemographic, clinical, biological, and pharmaceutical data pertaining to the patient and are performed in accordance with their health care objectives. Results: The preliminary results for the 39 TMRs performed to date (September 2021) showed that a total of 402 PIMs were detected, and all residents had at least one PIM. We also present the feasibility and the usefulness of this novel TMR for NH, illustrating these preliminary results with two concrete TMR experiences. Among the 39 TMR performed, the average acceptance rate of expert recommendations made to general practitioners (GP) working in NH was ∼33%. Discussion and Conclusions: The success of this novel TMR depends on how the proposed prescription adjustments made by the hospital expert team are subsequently integrated into health care practices. The low acceptance rate by GP highlights the need to actively involve these professionals in the process of developing TMR, with a view to encouraging them to act on proposed adjustments.
- Published
- 2022
- Full Text
- View/download PDF
8. [Telemedicine and drug iatrogenesis in nursing homes].
- Author
-
Montaleytang M, Correard F, Delalande G, Bourriquen M, and Daumas A
- Subjects
- Drug-Related Side Effects and Adverse Reactions, Humans, Inappropriate Prescribing, Quality of Life, Iatrogenic Disease, Nursing Homes, Telemedicine
- Abstract
Inappropriate drug prescribing is an avoidable cause of adverse drug events, sources of an increase in morbimortality, excess spending and a decrease in quality of life. Many actions exist to improve prescribing quality and to secure the medication circuit in nursing homes. As part of the deployment of telemedicine, the benefit of a medico-pharmaceutical tele-expertise system for medication is evident., (Copyright © 2019 Elsevier Masson SAS. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.